Article in Proceedings of the National Academy of Sciences of the United States of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed.
Proceedings of the National Academy of Sciences of the United States of America · 2025
Article
4 · The record
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors.
Xinqi XiDepartment of Biochemistry and Molecular Biology and Cancer Program, Biomedicine Discovery Institute, Monash University, Clayton, VIC 3800, Australia.ORCID 0009-0008-8388-5831
Ling LiuDepartment of Biochemistry and Molecular Biology and Cancer Program, Biomedicine Discovery Institute, Monash University, Clayton, VIC 3800, Australia.ORCID 0009-0001-3822-1111
Natasha TuanoMurdoch Children Research Institute, Parkville, VIC 3052, Australia.
Julien TailhadesDepartment of Biochemistry and Molecular Biology and Cancer Program, Biomedicine Discovery Institute, Monash University, Clayton, VIC 3800, Australia.
Dmitri MouradovPersonalised Oncology Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia.
Jason SteenClinical Genomics, School of Translational Medicine, Monash University, Melbourne, VIC 3168, Australia.
Oliver SieberPersonalised Oncology Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia.ORCID 0000-0001-9480-0786
Max CryleDepartment of Biochemistry and Molecular Biology and Cancer Program, Biomedicine Discovery Institute, Monash University, Clayton, VIC 3800, Australia.ORCID 0000-0002-9739-6157
Tu Nguyen-DumontClinical Genomics, School of Translational Medicine, Monash University, Melbourne, VIC 3168, Australia.ORCID 0000-0002-6217-0182
Eva SegelovDepartment of Clinical Research, Faculty of Medicine, University of Bern, Inselspital, Bern 3000, Switzerland.ORCID 0000-0002-4410-6144
Joseph RosenbluhDepartment of Biochemistry and Molecular Biology and Cancer Program, Biomedicine Discovery Institute, Monash University, Clayton, VIC 3800, Australia.ORCID 0000-0001-9815-8049
Funding
Federal Government | DHAC | National Health and Medical Research Council (NHMRC) 1140808Tour de Cure (TDC) RSP-225-18/19VicGovAu | Victorian Cancer Agency (VCA) MCRF20035VicGovAu | Victorian Cancer Agency (VCA) MCRF21029
6 · The paper itself
Abstract
Loss of the tumor suppressor gene (TSG) Adenomatous Polyposis Coli (
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.